No epidemiological studies have been conducted to assess the association of dietary vitamin K intake with the risk of pancreatic cancer. We used prospective data from the Prostate, Lung, Colorectal,… Click to show full abstract
No epidemiological studies have been conducted to assess the association of dietary vitamin K intake with the risk of pancreatic cancer. We used prospective data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial between 1993 and 2009 to fill this gap. A total of 101695 subjects were identified. Dietary intakes of phylloquinone (vitamin K1), menaquinones (vitamin K2), and dihydrophylloquinone (dihydrovitamin K1) were assessed with a food frequency questionnaire. Cox regression was applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). During a mean follow-up of 8.86 years (900744.57 person-years), 361 pancreatic cancer cases were documented. In the fully adjusted model, dietary intakes of phylloquinone (HRquartile 4 versus 1: 0.57; 95% CI: 0.39, 0.83; Ptrend=0.002) and dihydrophylloquinone (HRquartile 4 versus 1: 0.59; 95% CI: 0.41, 0.85; Ptrend=0.006), but not menaquinones (HRquartile 4 versus 1: 0.93; 95% CI: 0.65, 1.33; Ptrend=0.816), were found to be inversely associated with the risk of pancreatic cancer in a nonlinear dose-response manner (all Pnonlinearity<0.05), which were not modified by predefined stratification factors and remained in sensitivity analyses. In conclusion, dietary intakes of phylloquinone and dihydrophylloquinone, but not menaquinones, confer a reduced risk of pancreatic cancer. Future studies should confirm our findings.
               
Click one of the above tabs to view related content.